All-oral, interferon-free treatment for chronic hepatitis C: Cost-effectiveness analyses

Journal of Viral Hepatitis

Volumn 20, Issue 12, 2013, Pages 847-857

  Hagan, L M ^a,b,c   Yang, Z ^b   Ehteshami, M ^a,c   Schinazi, R F ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

antiviral agents; combination therapy; HCV; ribavirin; sustained virologic response; triple therapy

Indexed keywords

ANTIVIRUS AGENT; SOFOSBUVIR;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; STATISTICAL MODEL; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; COMBINATION THERAPY; HCV; RIBAVIRIN; SUSTAINED VIROLOGIC RESPONSE; TRIPLE THERAPY;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL;

EID: 84887617882     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12111     Document Type: Article

References (76)

1. World Health Organization [Internet]. Hepatitis C Fact Sheet [cited 2012 Jul 1]. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/index. html. (accessed 1 July 2012).
2. United States Department of Health and Human Services. Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care & Treatment of Viral Hepatitis. Washington, DC: United States Department of Health and Human Services, 2011. Available at: http://www.hhs.gov/ash/initiatives/ hepatitis/actionplan-viralhepatitis2011.pdf.
3. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD,. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156 (4): 271-278.
4. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB,. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011; 43 (1): 66-72.
5. Wong JB, McQuillan GM, McHutchison JG, Poynard T,. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90 (10): 1562-1569.
6. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156 (4): 263-270.
7. Centers for Disease Control and Prevention [Internet]. CDC Announces First ever National Hepatitis Testing Day and Proposes that all Baby Boomers be Tested once for Hepatitis C [cited 2012 July 22]. Available at: http://www.cdc.gov/nchhstp/newsroom/HepTestingRecsPressRelease2012.html. (accessed 22 July 2012).
8. Alter HJ, Liang TJ,. Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann Intern Med. 2012; 156 (4): 317-8.
9. Hoofnagle JH, Seeff LB,. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355 (23): 2444-2451.
10. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965.
11. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147 (10): 677-684.
12. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54 (4): 1433-1444.
13. National Institutes of Health. NIH consensus statement on management of hepatitis C. NIH Consens State Sci Statements 2002; 19 (3): 1-46.
14. Inciveck/telaprevir (package insert). Cambridge, MA: Vertex Pharmaceuticals. October 2012.
15. Victrelis/boceprevir (package insert). Whitehouse Station, NJ: Merck & Co, Inc. May 2011.
16. Schinazi RF, Bassit L, Gavegnano C,. HCV drug discovery aimed at viral eradication. J Viral Hepat 2010; 17 (2): 77-90.
17. Hagan LM, Schinazi RF,. Best strategies for global HCV eradication. Liver Int 2013; 33 (Suppl 1): 68-79.
18. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ,. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144 (10): 705-714.
19. El-Kamary SS, Jhaveri R, Shardell MD,. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011; 53 (2): 150-157.
20. National Center for Health Statistics [Internet]. Compressed Mortality File 1999-2007 Series 20 No. 2M, 2010. CDC WONDER on-line database. Hyattsville, MD: Centers for Disease Control and Prevention, 2010. [cited 2012 Jul 22]. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60-03.pdf.
21. Veldt BJ, Saracco G, Boyer N, Camma C, Bellobuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53 (10): 1504-1508.
22. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24 (2): 289-293.
23. Thein HH, Yi Q, Dore GJ, Krahn MD,. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48 (2): 418-431.
24. Davis GL, Albright JE, Cook SF, Rosenberg DM,. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9 (4): 331-338.
25. Ascher NL, Lake JR, Emond J, Roberts J,. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994; 20 (1 Pt 2): 24S-27S.
26. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL,. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127 (10): 855-865.
27. Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol 2009; 104 (5): 1147-1158.
28. Coffin PO, Scott JD, Golden MR, Sullivan SD,. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 2012; 54 (9): 1259-1271.
29. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011; 54 (2): 396-405.
30. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112 (2): 463-472.
31. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD,. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012; 156 (4): 279-290.
32. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ,. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10 (4 Pt 2): 1003-1019.
33. Center for Quality Management in Public Health. The State of Care for Veterans with Chronic Hepatitis C. Palo Alto, California: US Department of Veterans Affairs, Public Health Strategic Health Care Group, Center for Quality Management in Public Health., 2010. Available at: http://www.hepatitis.va.gov/ pdf/HCV-State-of-Care-2010.pdf.
34. Fink SA, Jacobson IM,. Managing patients with hepatitis-B-related or hepatitis-C-related decompensated cirrhosis. Nat Rev Gastroenterol Hepatol 2011; 8 (5): 285-295.
35. Pol S, Carnot F, Nalpas B, Lagneau JL, Fontaine H, Serpaggi J, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol 2004; 35 (1): 107-112.
36. Pearlman BL, Traub N,. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52 (7): 889-900.
37. Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135 (3): 821-829.
38. Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149 (6): 399-403.
39. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM,. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49 (3): 729-738.
40. Balart LA, Lisker-Melman M, Hamzeh FM, Kwok A, Lentz E, Rodriguez-Torres M,. Peginterferon alpha-2a plus ribavirin in Latino and non-Latino whites with HCV genotype 1: histologic outcomes and tolerability from the LATINO Study. Am J Gastroenterol 2010; 105 (10): 2177-2185.
41. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122 (5): 1303-1313.
42. Iacobellis A, Perri F, Valvano MR, Caruso N, Niro GA, Andriulli A,. Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol 2011; 9 (3): 249-253.
43. UBS Securities, LLC. UBS Q-series: is the HCV market investable long term? A new analysis of diagnosis and treatment rates. New York, NY: UBS Investment Research, 2012.
44. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ,. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290 (2): 228-237.
45. Kowdley K, Lawitz E, Poordad F, Cohen D, Nelson D, Zeuzem S, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders with HCV genotype 1 infection. Proceedings of The Liver Meeting, 63rd Annual Meeting of the American Association for the Study of Liver Diseases; 2012 Nov 9-13; Boston, Massachusetts, USA.
46. Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2012; doi: 10.1016/j.jhep.2012.09.037.
47. Cardoso A, Moucari R, Giuily N, Figueiredo-Mendes C, Boyer N, Ripault M, et al. Sustained virological response is associated with reversibility of cirrhosis in chronic hepatitis C patients. Proceedings of the International Liver Congress, 47th Annual Meeting of the European Association for the Study of the Liver; 2012 April 18-22; Barcelona, Spain.
48. Bini EJ, Brau N, Currie S, Shen H, Anand BS, Hu KQ, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100 (8): 1772-1779.
49. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK,. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56 (3): 385-389.
50. Singer ME, Younossi ZM,. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 2001; 111 (8): 614-621.
51. Spaulding AC, Thomas DL,. Screening for HCV infection in jails. JAMA 2012; 307 (12): 1259-1260.
52. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357 (2): 124-134.
53. Groom H, Dieperink E, Nelson DB, Garrard J, Johnson JR, Ewing SL, et al. Outcomes of a hepatitis C screening program at a large urban VA medical center. J Clin Gastroenterol 2008; 42 (1): 97-106.
54. Putka B, Mullen K, Birdi S, Merheb M,. The disposition of hepatitis C antibody-positive patients in an urban hospital. J Viral Hepat 2009; 16 (11): 814-821.
55. Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess 2006; 10 (32): iii-iv, ix-xii, 1-93.
56. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43 (3): 425-433.
57. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013; 368 (1): 34-44.
58. Lawitz E, Poordad F, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al. A phase 2a trial of 12-week interferon-free therapy with two direct-activing antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol 2013; doi: 10.1016/j.jhep.2013.02.009.
59. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013; 368 (1): 45-53.
60. Sulkowski M, Gardiner D, Lawitz E, Hinestrosa F, Nelson D, Thuluvath P, et al. Potent viral suppression with the all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (nucleoside NS5B inhibitor), +/- ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3 (100% SVR GT1, 91% GT2). Proceedings of the International Liver Congress, 47th Annual Meeting of the European Association for the Study of the Liver; 2012 April 18-22; Barcelona, Spain.
61. Zeuzem S, Soriano V, Asselah T, Bronowicki J, Lohse A, Müllhaupt B, et al. SOUND-C2 interim results: high efficacy, good safety profile of IFN-free BI 201335, BI 207127, and RBV combination therapy in treatment-naive patients with genotype 1 HCV. Proceedings of the International Liver Congress, 47th Annual Meeting of the European Association for the Study of the Liver; 2012 April 18-22; Barcelona, Spain.
62. Foster GR, Goldin RD, Main J, Murray-Lyon I, Hargreaves S, Thomas HC,. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ 1997; 315 (7106): 453-458.
63. Irving WL, Smith S, Cater R, Pugh S, Neal KR, Coupland CA, et al. Clinical pathways for patients with newly diagnosed hepatitis C-what actually happens. J Viral Hepat 2006; 13 (4): 264-271.
64. Pawlotsky J, Sarin S, Foster G, Peng C, Rasenack J, Flisiak R, et al. Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study. Proceedings of The Liver Meeting, 63rd Annual Meeting of the American Association for the Study of Liver Diseases; 2012 Nov 9-13; Boston, Massachusetts, USA.
65. Sulkowski M, Gardiner D, Rodriguez-Torres M, Reddy R, Hassanein T, Jacobson I, et al. High rate of sustained virologic response with the all-oral combination of Daclatasvir (NS5A inhibitor) plus Sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3. Proceedings of The Liver Meeting, 63rd Annual Meeting of the American Association for the Study of Liver Diseases; 2012 Nov 9-13; Boston, Massachusetts, USA.
66. Thein HH, Krahn M, Kaldor JM, Dore GJ,. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol 2005; 100 (3): 643-651.
67. Ratcliffe J, Longworth L, Young T, Bryan S, Burroughs A, Buxton M,. Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl 2002; 8 (3): 263-270.
68. Thompson CJ, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Brit J Cancer 2008; 98 (7): 1166-1175.
69. Bownik H, Saab S,. The effects of hepatitis C recurrence on health-related quality of life in liver transplant recipients. Liver Int 2010; 30 (1): 19-30.
70. McLernon DJ, Dillon J, Donnan PT,. Health-state utilities in liver disease: a systematic review. Med Decis Making 2008; 28 (4): 582-592.
71. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ,. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl 2010; 16 (6): 748-759.
72. Younossi ZM, Singer ME, McHutchison JG, Shermock KM,. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30 (5): 1318-1324.
73. Brown DM, Everhart JE,. Cost of digestive diseases in the United States. Bethesda, MD: Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1994.
74. Naugler WE, Sonnenberg A,. Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. Liver Transpl 2010; 16 (10): 1186-1194.
75. Showstack J, Katz PP, Lake JR, Brown RS Jr, Dudley RA, Belle S, et al. Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA 1999; 281 (15): 1381-1386.
76. Wong JB, Bennett WG, Koff RS, Pauker SG,. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998; 280 (24): 2088-2093.